Skip to main content

Table 2 Baseline participant demographics and clinical characteristics

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

Characteristic

Octreotide

N = 52

Placebo

N = 54

Age in years, mean (SD)

62.9 (13.6)

66.3 (12.2)

Gender, female, n (%)

47 (90.4)

38 (70.4)

Performance status (AKPS), median (IQR)

50 (40–60)

50 (40–60)

BPI pain score, median (IQR)

3 (1–5)

4 (1.25–5)

Nauseaa, median (IQR)

2 (1–2)

1(1–2)

Level of bowel obstruction

 Gastric outlet/duodenal, n (%)

5 (9.6)

9 (16.7)

 Small bowel/ multi-level, n (%)

34 (65.4)

34 (63.0)

 Large bowel, n (%)

2 (3.9)

3 (5.6)

 Indeterminate, n (%)

11 (21.2)

8 (14.8)

EORTC QLQ-C15-Pal overall quality of life score, mean (SD)

22.1 (24.3)

31.5 (27.2)

  1. AKPS Australia-modified Karnofsky Performance Status scale, scores range from 0 to 100 where a higher score indicates better performance in terms of work, activity and self-care, BPI Brief Pain Inventory, scores range from 0 to 10 where higher score represents more pain, EORTC QLQ-C15-Pal The European Organization for Research and Treatment of Cancer quality of life palliative care questionnaire, scores range from 0 to 100 and higher scores represent better QOL, IQR Inter-quartile range, SD Standard deviation
  2. anausea numerical rating scale ranges from 0 to 5, where a higher score indicates more nausea